The anti-MM effect of the anti-CD38 mAb Daratumumab was also potentiated by the combination with proteasome inhibitors (PIs), such as Bortezomib and Carfilzomib [11,12]. This evidence concerns the gene CD38 and Miyoshi myopathy.